Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN84,3584,380,39
Msft1,58
Nokia4,3894,48-0,27
IBM1,50
Mercedes-Benz Group AG50,1950,21-1,01
PFE0,24
04.07.2025 18:00:42
Indexy online
AD Index online
select
AD Index online
 

  • 04.07.2025 17:35:00
PureTech Health (London)
Závěr k 4.7.2025 Změna (%) Změna (GBP) Objem obchodů (GBP)
1,29 -0,62 -0,01 59 071
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 05.07.2025
Popis společnosti
Obecné informace
Název společnostiPuretech Health PLC
TickerPRTC
Kmenové akcie:Ordinary Shares
RICPRTC.L
ISINGB00BY2Z0H74
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 31.12.2024 56
Akcie v oběhu k 30.06.2025 240 254 449
MěnaUSD
Kontaktní informace
Ulice6 Tide Street, Suite 400
MěstoBOSTON
PSČ02210
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 174 822 333
Fax16174823337

Business Summary: PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Puretech Health PLC revenues increased 45% to $4.8M. Net income totaled $53.5M vs. loss of $65.7M. Revenues reflect Parent company & other segment increase from $1.7M to $4.3M. Net Income reflects Gain/(loss) on deconsolidation of subsid increase from $61.8M to $151.8M (income), Gain/(loss) on investments in notes from increase from $27.6M (expense) to $13.1M (income).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 05.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, DirectorEric Elenko-09.04.2024
Chief Executive Officer, DirectorBharatt Chowrira6009.04.2024
Co-Founder, Non-Executive DirectorRobert Langer76
General Counsel, Company SecretaryCharles Sherwood7725.04.202425.04.2024
Chief Portfolio OfficerRobert Lyne-01.01.2023